减肥药巨头丹麦药厂诺和诺德(NVO.US)在目前的美股夜盘交易中大涨近10%，报52.79美元。消息面上，诺和诺德表示，美国食品药物管理局(FDA)周一批准了诺和盈(Wegovy，成分为司美格鲁肽)药片作为口服GLP-1上市。 Wegovy口服片是首个获批用于体重管理的口服GLP-1受体激动剂药物。此次批准依据是OASIS试验项目和SELECT试验。在OASIS 4试验中，每日一次口服25毫克司美格鲁肽，平均减重16.6%。服用Wegovy口服片剂所达到的减肥效果，与注射用Wegovy 2.4毫克类似。Wegovy口服片预计将于2026年1月初在美国上市。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.